2. Gene
  3. Gaa - alpha glucosidase Gene

Gaa - alpha glucosidase Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Rattus norvegicus
Gene ID: 367562 | Gene type: protein coding

About Gaa

Summary

Enables alpha-1,4-glucosidase activity and carbohydrate binding activity. Involved in glycogen catabolic process. Located in lysosome. Human ortholog(s) of this gene implicated in glycogen storage disease II. Orthologous to human GAA (alpha glucosidase). [provided by Alliance of Genome Resources, Apr 2022]

Gaa Products(1)

mRNA Protein Name
NM_199118.1 NP_954549.1 lysosomal alpha-glucosidase precursor
Gene Ontology
  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence Reference Source
enables alpha-1,4-glucosidase activity IDA
IDA: Inferred from direct assay
8702598 RGD
enables alpha-1,4-glucosidase activity IMP
IMP: Inferred from mutant phenotype
2193931 RGD
enables carbohydrate binding IDA
IDA: Inferred from direct assay
8702598 RGD
Biological Process GO Annotation Evidence Reference Source
involved in glycogen catabolic process IDA
IDA: Inferred from direct assay
8710802 RGD
involved in glycogen catabolic process IMP
IMP: Inferred from mutant phenotype
2193931 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

lysosomal alpha-glucosidase

acid (Pompe disease, glycogen storage disease type II)

acid alpha-glucosidase

acid maltase

glucosidase, alpha, acid

glucosidase, alpha

acid (Pompe disease, glycogen storage disease type II)

Related Agents

Approval
Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-132609 Patisiran sodium 99.09% Unkown
HY-132608 Inotersen sodium 96.44% Unkown
HY-108753 Eteplirsen 98.50% Unkown
HY-132611 Golodirsen Modulator 92.00% Unkown
HY-132586 Viltolarsen Modulator 92.75% Unkown
Clinical Phase
Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Phase
HY-147217 Bepirovirsen Inhibitor 98.44% Phase 3
HY-132596 Tivanisiran Inhibitor 92.62% Phase 3
HY-147412 Ultevursen / Phase 3
HY-150724 ODN 1018 Agonist 96.23% Phase 2
HY-132602 Remlarsen Agonist 92.27% Phase 2
HY-148100 Emapticap pegol Inhibitor / Phase 2
Pre-clinical Phase
Bioactive Molecules (13)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-150738 ODN 2088 Antagonist 93.63% Unkown
HY-150750 ODN M362 93.61% Unkown
HY-150736 ODN 20844 Inhibitor 92.60% Unkown
HY-145725A Baliforsen Inhibitor 94.33% Unkown
HY-150744 ODN 24888 Inhibitor / Unkown
HY-144124 5-C-heptyl-DNJ Inhibitor / Unkown
HY-150215 ODN 105870 Inhibitor / Unkown
HY-150740 ODN 21595 Inhibitor / Unkown
HY-154995 N-4′-(p-Trifluoromethylphenyl)butyl-DAB Inhibitor / Unkown
HY-E70183 Lysosomal α-Glucosidase / Unkown
HY-RS05196 GAA Human Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS17242 Gaa Mouse Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS23696 Gaa Rat Pre-designed siRNA Set A Pre-designed Sets / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gaa NCBI NCBI:2548